On September 28, Abivax S.A. rose 5.1% in regular trading, trading at $95.33 USD/share, with Turnover of $44.18 million.

Within the Biotechnology sector where Abivax S.A. belongs, individual stock performance was sharply divergent. Among individual stocks, Kodiak Sciences Inc. up 155.58%, Moderna, Inc. down 2.65%, Amgen down 0.05%, Gilead Sciences down 0.19%, Regeneron Pharmaceuticals down 3.45%.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is being evaluated in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, with the company planning to submit a New Drug Application before year-end.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)